Despite the improved pathological complete response rate in HER2‐positive breast cancer patients with neoadjuvant dual HER2 blockade, it would be desirable to identify patients exquisitely responsive to single agent trastuzumab to minimize or avoid overtreatment. The gene discussed is ERBB2; the disease is breast carcinoma.